



Ibalizumab Phase III Study Primary End-Point Results To Be Presented At IDWEEK 2016

August 18, 2016

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that the abstract for the primary end-point results of the ibalizumab phase III study (TMB-301) has been selected for a late breaker oral presentation at the IDWeek Conference to be held in New Orleans, LA, from October 26 to 30, 2016.